Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

State of art in systemic management of nmCRPC

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.05.19
Views: 192

Prof Stéphane Oudard - Georges Pompidou Hospital, Paris, France

Prof Stéphane Oudard speaks to ecancer at the 2019 International Gastrointestinal, Liver and Uro-Oncology Conference (IGILUC) in Cairo about the systemic management of non-metastatic castration-resistant prostate cancer (nmCRPC) and what is new in this indication.

He explains that there are three drugs being used in this setting: apalutamide, enzalutamide and darolutamide.

Prof Oudard explains that, although the three drugs had similar hazard ratios, the toxicities did differ.

However due to the differing frequency patients were across the studies, they are not fully comparable.

Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation